Exact Sciences Corporation
EXAS
주식 순위
#1154
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
주가
$104.91
마지막 동기화: 2026-03-23
시가총액
$20.03B
변동 (1일)
0.00%
변동 (1년)
65.45%
국가
US
거래 Exact Sciences Corporation (EXAS)
카테고리
Healthcare
Exact Sciences Corporation (EXAS)의 매출
Dec 2025 기준 매출 TTM: $3.25B
Exact Sciences Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $3.25B입니다. 2024년에 회사는 $2.76B의 수익을 올렸으며 이는 2023년의 $2.50B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Exact Sciences Corporation의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $3.25B | 0.00% |
| 2025 | $3.25B | 17.69% |
| 2024 | $2.76B | 10.37% |
| 2023 | $2.50B | 19.93% |
| 2022 | $2.08B | 17.95% |
| 2021 | $1.77B | 18.49% |
| 2020 | $1.49B | 70.19% |
| 2019 | $876.29M | 92.82% |
| 2018 | $454.46M | 70.86% |
| 2017 | $265.99M | 167.66% |
| 2016 | $99.38M | 151.99% |
| 2015 | $39.44M | 2,093.38% |
| 2014 | $1.80M | -56.61% |
| 2013 | $4.14M | 0.00% |
| 2012 | $4.14M | -0.46% |
| 2011 | $4.16M | -22.10% |
| 2010 | $5.34M | 12.32% |
| 2009 | $4.76M | -648.79% |
| 2008 | $-867.00K | -129.54% |
| 2007 | $2.94M | -38.21% |
| 2006 | $4.75M | 11.76% |
| 2005 | $4.25M | -13.88% |
| 2004 | $4.94M | 70.11% |
| 2003 | $2.90M | 223.41% |
| 2002 | $897.00K | 1,663.32% |
| 2001 | $50.87K | 0.00% |
| 2000 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $46.34B | 1,327.04% |
US
|
|
| $25.11B | 673.24% |
US
|
|
| $2.71B | -16.63% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 127.04% |
US
|
